TELIX Pharmaceuticals Ltd

TLX.AX · Moat type: REGULIERUNG

MoatScore

3/10

Fair Value

n/a

Margin of Safety

n/a

Rating

SCHWACH

Telix Pharmaceuticals develops and markets radiopharmaceutical products that use radioactively labeled molecules for the diagnosis and treatment of cancer (primarily prostate cancer and renal cancer), with revenue generated mainly from the commercial distribution of approved diagnostic radiopharmaceuticals as well as from a growing pipeline of clinical candidates.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.